A critical appraisal of the rate pressure product as index of myocardial oxygen consumption for the study of metabolic coronary flow regulation.
For the assessment of metabolic coronary vasodilatation, changes in systolic rate pressure product (RPP) are frequently used to estimate the pacing- or exercise induced changes in myocardial oxygen consumption (MVO2). The present study was designed to test whether this is justified in patients with coronary artery disease. To study the relation between RPP and changes in MVO2 under different conditions, we used data from 21 patients who participated in two previous studies investigating the effect of nitroglycerin (NTG) and anaesthesia on metabolic coronary flow regulation. At control, during administration of NTG 1 microg/kg/min (n=11), and during anaesthesia (n=10), coronary sinus blood flow, MVO2 and RPP were measured at sinus rhythm and during atrial pacing (30 bpm above sinus rate) and the relation between the percentage increase in RPP (delta%RPP) and MVO2 delta%MVO2) was analysed, using standard linear regression analysis. Although a significant relation between delta%MVO2 and delta%RPP was found at control and during anaesthesia, prediction intervals were very wide and only 40% and 60% of the variation in delta%MVO2, respectively, could be explained by the variation in delta%RPP. During administration of NTG 1 microg/kg/min no significant relation was found between delta%MVO2 and delta%RPP. Thus, for the study of metabolic coronary flow regulation, pacing induced changes in MVO2 cannot be predicted accurately from changes in RPP.
Kal
J E
JE
Department of Anaesthesiology, Cardiovascular Research Institute Amsterdam, Academic Medical Center, The Netherlands. J.E.Kal@amc.uva.nl
Van Wezel
H B
HB
Vergroesen
I
I
D000768:Anesthesia, General; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D002304:Cardiac Pacing, Artificial; D001026:Coronary Artery Bypass; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology*; D003327:Coronary Disease / Q000503:physiopathology* / Q000601:surgery; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology*; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology*; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007262:Infusions, Intravenous; D009206:Myocardium / Q000378:metabolism*; D005996:Nitroglycerin / Q000008:administration & dosage; D010101:Oxygen Consumption / Q000187:drug effects / Q000502:physiology*; D014665:Vasodilator Agents / Q000008:administration & dosage
D014665:Vasodilator Agents; D005996:Nitroglycerin